E
Novavax, Inc.
NVAX
$7.95
-$0.43-5.13%
E
Sell
1/30/2025Downgrade
Novavax, Inc. (NVAX) was downgraded to E+ from D- on 1/30/2025 due to a significant decline in the growth index and volatility index. EBIT declined 180.09% from $162.1M to -$129.82M, earnings per share declined from $0.9948 to -$0.7579, and operating cash flow declined 146.08% from $314.27M to -$144.81M.
Novavax, Inc. (NVAX) was downgraded to E+ from D- on 1/30/2025 due to a significant decline in the growth index and volatility index. EBIT declined 180.09% from $162.1M to -$129.82M, earnings per share declined from $0.9948 to -$0.7579, and operating cash flow declined 146.08% from $314.27M to -$144.81M.
D
Sell
6/3/2024Upgraded
Novavax, Inc. (NVAX) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index.
Novavax, Inc. (NVAX) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index.
E
Sell
4/24/2023Downgrade
Novavax, Inc. (NVAX) was downgraded to E+ from D- on 4/24/2023 due to a decline in the total return index and volatility index.
Novavax, Inc. (NVAX) was downgraded to E+ from D- on 4/24/2023 due to a decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
Novavax, Inc. (NVAX) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.83 to 0.58, and debt to equity increased from -1 to -0.84.
Novavax, Inc. (NVAX) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.83 to 0.58, and debt to equity increased from -1 to -0.84.
D
Sell
2/23/2023Upgraded
Novavax, Inc. (NVAX) was upgraded to D from D- on 02/23/2023.
Novavax, Inc. (NVAX) was upgraded to D from D- on 02/23/2023.
D
Sell
2/8/2023Downgrade
Novavax, Inc. (NVAX) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index, total return index and volatility index. Debt to equity increased from -1.16 to -1.
Novavax, Inc. (NVAX) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index, total return index and volatility index. Debt to equity increased from -1.16 to -1.
D
Sell
5/16/2022Upgraded
Novavax, Inc. (NVAX) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Novavax, Inc. (NVAX) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Novavax, Inc. (NVAX) was downgraded to E+ from D on 5/13/2022 due to a decline in the valuation index and solvency index. Debt to equity increased from -1.38 to 7.22.
Novavax, Inc. (NVAX) was downgraded to E+ from D on 5/13/2022 due to a decline in the valuation index and solvency index. Debt to equity increased from -1.38 to 7.22.
D
Sell
5/5/2022Upgraded
Novavax, Inc. (NVAX) was upgraded to D from D- on 05/05/2022.
Novavax, Inc. (NVAX) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Novavax, Inc. (NVAX) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.17 to 0.82.
Novavax, Inc. (NVAX) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, total return index and volatility index. The quick ratio declined from 1.17 to 0.82.
D
Sell
11/23/2021Upgraded
Novavax, Inc. (NVAX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and volatility index.
Novavax, Inc. (NVAX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and volatility index.
D
Sell
11/8/2021Downgrade
Novavax, Inc. (NVAX) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 198.43% from $144.41M to -$142.14M, and total revenue declined 39.99% from $298.02M to $178.84M.
Novavax, Inc. (NVAX) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 198.43% from $144.41M to -$142.14M, and total revenue declined 39.99% from $298.02M to $178.84M.
D
Sell
5/1/2020Upgraded
Novavax, Inc. (NVAX) was upgraded to D from D- on 5/1/2020 due to a significant increase in the growth index and valuation index. Total revenue increased 251.66% from $2.51M to $8.82M, and operating cash flow increased 26.4% from -$32.26M to -$23.74M.
Novavax, Inc. (NVAX) was upgraded to D from D- on 5/1/2020 due to a significant increase in the growth index and valuation index. Total revenue increased 251.66% from $2.51M to $8.82M, and operating cash flow increased 26.4% from -$32.26M to -$23.74M.
D
Sell
8/10/2016Downgrade
Novavax, Inc. (NVAX) was downgraded to D- from D on 8/10/2016 due to a decline in the growth index, efficiency index and solvency index. Debt to equity increased from 1.7 to 2.87, total revenue declined 40.61% from $4.22M to $2.51M, and the quick ratio declined from 6.11 to 4.48.
Novavax, Inc. (NVAX) was downgraded to D- from D on 8/10/2016 due to a decline in the growth index, efficiency index and solvency index. Debt to equity increased from 1.7 to 2.87, total revenue declined 40.61% from $4.22M to $2.51M, and the quick ratio declined from 6.11 to 4.48.
D
Sell
5/6/2016Upgraded
Novavax, Inc. (NVAX) was upgraded to D from D- on 5/6/2016 due to an increase in the efficiency index and total return index. Total capital increased 70.94% from $293.06M to $500.96M, and net income increased 1.97% from -$78.81M to -$77.25M.
Novavax, Inc. (NVAX) was upgraded to D from D- on 5/6/2016 due to an increase in the efficiency index and total return index. Total capital increased 70.94% from $293.06M to $500.96M, and net income increased 1.97% from -$78.81M to -$77.25M.
D
Sell
3/22/2016Downgrade
Novavax, Inc. (NVAX) was downgraded to D- from D on 3/22/2016 due to a significant decline in the volatility index, total return index and valuation index.
Novavax, Inc. (NVAX) was downgraded to D- from D on 3/22/2016 due to a significant decline in the volatility index, total return index and valuation index.
D
Sell
3/1/2016Downgrade
Novavax, Inc. (NVAX) was downgraded to D from D+ on 3/1/2016 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 11.84 to 3.05, and total capital declined 20.27% from $367.55M to $293.06M.
Novavax, Inc. (NVAX) was downgraded to D from D+ on 3/1/2016 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 11.84 to 3.05, and total capital declined 20.27% from $367.55M to $293.06M.
D
Sell
2/29/2016Downgrade
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 2/29/2016 due to a decline in the total return index and volatility index.
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 2/29/2016 due to a decline in the total return index and volatility index.
C
Hold
2/3/2016Upgraded
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 2/3/2016 due to an increase in the valuation index and efficiency index. Net income increased 60.46% from -$20.64M to -$33.12M.
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 2/3/2016 due to an increase in the valuation index and efficiency index. Net income increased 60.46% from -$20.64M to -$33.12M.
D
Sell
8/12/2015Downgrade
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 8/12/2015 due to a decline in the growth index, solvency index and efficiency index. Operating cash flow declined 59.59% from -$30.49M to -$12.32M, earnings per share declined from -$0.101 to -$0.077, and net income declined 15.3% from -$24.37M to -$20.64M.
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 8/12/2015 due to a decline in the growth index, solvency index and efficiency index. Operating cash flow declined 59.59% from -$30.49M to -$12.32M, earnings per share declined from -$0.101 to -$0.077, and net income declined 15.3% from -$24.37M to -$20.64M.
C
Hold
5/8/2015Upgraded
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 5/8/2015 due to a noticeable increase in the growth index, solvency index and efficiency index. The quick ratio increased from 5.24 to 11.77, total capital increased 73.68% from $230.62M to $400.54M, and operating cash flow increased 54.24% from -$19.77M to -$30.49M.
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 5/8/2015 due to a noticeable increase in the growth index, solvency index and efficiency index. The quick ratio increased from 5.24 to 11.77, total capital increased 73.68% from $230.62M to $400.54M, and operating cash flow increased 54.24% from -$19.77M to -$30.49M.
D
Sell
3/2/2015Downgrade
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 3/2/2015 due to a decline in the valuation index, solvency index and efficiency index. The quick ratio declined from 9.94 to 5.24, and total capital declined 12.4% from $263.26M to $230.62M.
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 3/2/2015 due to a decline in the valuation index, solvency index and efficiency index. The quick ratio declined from 9.94 to 5.24, and total capital declined 12.4% from $263.26M to $230.62M.
C
Hold
8/8/2014Upgraded
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 8/8/2014 due to a large increase in the volatility index, valuation index and solvency index. The quick ratio increased from 9 to 9.21.
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 8/8/2014 due to a large increase in the volatility index, valuation index and solvency index. The quick ratio increased from 9 to 9.21.
D
Sell
5/12/2014Downgrade
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 5/12/2014 due to a large decline in the total return index, efficiency index and growth index. Total revenue declined 14.7% from $8.75M to $7.46M, total capital declined 6.01% from $205.42M to $193.07M, and earnings per share declined from -$0.0674 to -$0.0661.
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 5/12/2014 due to a large decline in the total return index, efficiency index and growth index. Total revenue declined 14.7% from $8.75M to $7.46M, total capital declined 6.01% from $205.42M to $193.07M, and earnings per share declined from -$0.0674 to -$0.0661.
C
Hold
4/10/2014Upgraded
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 4/10/2014 due to a large increase in the total return index, valuation index and volatility index.
Novavax, Inc. (NVAX) was upgraded to C- from D+ on 4/10/2014 due to a large increase in the total return index, valuation index and volatility index.
D
Sell
3/26/2014Downgrade
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 3/26/2014 due to a large decline in the total return index, valuation index and volatility index.
Novavax, Inc. (NVAX) was downgraded to D+ from C- on 3/26/2014 due to a large decline in the total return index, valuation index and volatility index.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
